Lipid-lowering agents (Artovastatin)
PreclinicalSmall molecule
Lipid-lowering agents (Artovastatin) is one of 45 small molecule programs targeting Dermatomyositis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
49 competitors in Dermatomyositis
#DrugCompanyPhaseTrials
1Xeljanz
PPrism Pharmaceuticals
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Olumiant
Eli LillyPhase 3
Stelara
Johnson & JohnsonPhase 3
JAK Inhibitor
FFred Hutchinson Cancer Center
Approved
Proleukin
IIovance Biotherapeutics, Inc.
Phase 3
Otezla
AmgenPhase 2
Actemra
RochePhase 2
Ultomiris
AstraZenecaPhase 2
Jakafi
IncytePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Sao Paulo